ArticlePharmaceutical research2010
Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Resveratrol plus carboxymethyl-β-glucan in children with recurrent respiratory infections: a preliminary and real-life experience.Italian journal of pediatrics · 2014Trial
- Protective effects of curcumin and resveratrol on neurodegeneration and cognitive dysfunction in a streptozotocin-induced alzheimer rat model.Scientific reports · 2026Article
- Bioceramic bone tissue-engineered substitutes with anti-inflammatory effects in periodontitis.Frontiers in bioengineering and biotechnology · 2026Review
- The Additive Antinociceptive Effect of Resveratrol and Ketorolac in the Formalin Test in Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Resolvin E1 Reduces Tumor Growth in a Xenograft Model of Lung Cancer.The American journal of pathology · 2022Article
- Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022Review
- Curcumae Ameliorates Diethylnitrosamine-Induced Hepatocellular Carcinoma via Alteration of Oxidative Stress, Inflammation and Gut Microbiota.Journal of inflammation research · 2021Article
- Resveratrol in Cancer Patients: From Bench to Bedside.International journal of molecular sciences · 2020Review
- MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer.Molecular therapy. Nucleic acids · 2019Article
- Pterostilbene 4'-Oxidative medicine and cellular longevity · 2018Article
- Inhibition of NF-κB Signaling Pathway by Resveratrol Improves Spinal Cord Injury.Frontiers in neuroscience · 2018Review
- The Role of Resveratrol in Cancer Therapy.International journal of molecular sciences · 2017Review
- Resveratrol, Potential Therapeutic Interest in Joint Disorders: A Critical Narrative Review.Nutrients · 2017Review
- New Insights into the Epigenetics of Hepatocellular Carcinoma.BioMed research international · 2017Review
- Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.International journal of nanomedicine · 2017Article
- The effect of resveratrol on the recurrent attacks of gouty arthritis.Clinical rheumatology · 2016Article
- Role of Natural Stilbenes in the Prevention of Cancer.Oxidative medicine and cellular longevity · 2016Review
- Critical review of resveratrol in xenobiotic-induced hepatotoxicity.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2015Review
- Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.Seminars in cancer biology · 2015Review
- A multi-targeted approach to suppress tumor-promoting inflammation.Seminars in cancer biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResveratrol, present in grapes and red wine, has been found to prevent diethylnitrosamine (DENA)-initiated rat liver tumorigenesis, though the chemopreventive mechanisms are not completely elucidated. The current study was designed to explore whether the antiinflammatory properties of resveratrol play a role in its antihepatocarcinogenic action.
methodsLiver samples were harvested from a 20-week chemopreventive study in which resveratrol (50, 100 and 300 mg/kg) was shown to inhibit DENA-induced hepatocyte nodules in Sprague-Dawley rats in a dose-responsive manner. Hepatic preneoplastic and inflammatory markers, namely heat shock protein (HSP70), cyclooxygenase-2 (COX-2) and nuclear factor-kappaB (NF-kappaB), were studied using immunohistochemical as well as Western blot techniques.
resultsResveratrol dose-dependently suppressed DENA-induced increased expressions of hepatic HSP70 and COX-2. Resveratrol also attenuated the DENA-mediated translocation of NF-kappaB p65 from the cytosol to the nucleus with stabilization of inhibitory kappaB.
conclusionThe present findings indicate that resveratrol exerts chemoprevention of hepatocarcinogenesis possibly through antiinflammatory effects during DENA-evoked rat liver carcinogenesis by suppressing elevated levels of HSP70, COX-2 as well as NF-kappaB. These beneficial effects combined with an excellent safety profile encourage the development of resveratrol for chemoprevention and intervention of human HCC that remains a devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.